Eric S. Fain, Director at Orchestra BioMed Holdings, Inc. (OBIO), bought 20,000 shares at $4.13 ($83K) on 2026-05-14, disclosed to the SEC on 2026-05-18.
Director Eric S. Fain purchased 20,000 shares of Orchestra BioMed for $82,600, marking the largest insider purchase in the company's history. This significant buy signals insider confidence in the stock's potential recovery following recent volatility.
OBIO is trading at $3.98, down 12.81% over the last 30 days but up 37.24% over the past year, currently sitting 26.62% below its 52-week high of $5.42.
1) Q2 earnings on August 10, 2026, where the company missed revenue estimates by 32.31%; 2) TD Cowen initiated coverage with a Buy rating and $15 price target on December 31, 2025; 3) The company reported a massive earnings surprise of +168.87% for Q4 2025 on March 12, 2026.
1) The stock is currently trading at a forward P/E of -2.91, indicating negative earnings expectations; 2) Short interest represents 6.55% of the float, which could lead to volatility if the stock rallies.
Something here stands out, but not much.
| Filing → |
| OBIO | SELL | 2024-09-10 | $31K | — | Filing → |
| STJ | SELL | 2015-04-28 | $3.5M | — | Filing → |
| STJ | SELL | 2013-10-22 | $8.2M | — | Filing → |